Oxyntomodulin: Complete Research Profile — The Endogenous Dual GLP-1/Glucagon Agonist Bridging Metabolic and Gut-Brain Research (2026)

# Oxyntomodulin: Complete Research Profile — The Endogenous Dual GLP-1/Glucagon Agonist Bridging Metabolic and Gut-Brain Research (2026)

Oxyntomodulin (OXM) occupies a unique position in endocrine biology: it is the body's own unimolecular dual agonist, simultaneously activating the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) from a single 37-amino acid peptide scaffold. Long overshadowed by its more famous proglucagon-derived siblings — GLP-1 and glucagon — oxyntomodulin has attracted intense renewed interest as researchers seek to understand how its unique receptor pharmacology produces a metabolic phenotype distinct from either parent hormone alone.

The clinical relevance of understanding oxyntomodulin has never been higher. The dual GLP-1/glucagon agonist drug class — exemplified by mazdutide and survodutide — is built directly on the oxyntomodulin pharmacophore. Decoding the endogenous peptide's biology is prerequisite to understanding how, and why, these optimized analogs achieve their metabolic effects in preclinical and clinical research. This research profile covers oxyntomodulin's biosynthesis, molecular structure, receptor pharmacology, physiological actions, secretion kinetics, clinical research record, and its role as the progenitor template for an entire drug class.

> Research Use Only (RUO): Oxyntomodulin and all information presented here are for laboratory and scientific research purposes only. This content does not constitute medical advice, dosing guidance, or clinical protocols.

---

Biosynthesis: Proglucagon Processing and Tissue-Specific Cleavage

Oxyntomodulin does not arise from a dedicated gene. It is a post-translational product of the proglucagon gene (GCG), which encodes a 160-amino acid preproglucagon precursor that yields a strikingly different array of biologically active peptides depending on the tissue in which it is processed.

The Proglucagon Gene and Differential Processing

In pancreatic alpha cells, prohormone convertase 2 (PC2) cleaves proglucagon to generate mature glucagon (29 aa), GRPP (glicentin-related pancreatic polypeptide), and the major proglucagon fragment (MPGF) — a large C-terminal fragment that contains the GLP-1 and GLP-2 sequences but remains largely inactive in this tissue.

In intestinal L-cells and neurons of the brainstem nucleus tractus solitarius (NTS), prohormone convertase 1/3 (PC1/3) follows a fundamentally different cleavage pattern. Here, the MPGF is processed into GLP-1 (7-36 amide or 7-37), GLP-2, and — critically — glicentin and its further cleavage product, oxyntomodulin. Glicentin (69 aa) is processed by removal of the GRPP N-terminal extension to yield mature oxyntomodulin (37 aa), which contains the complete 29-amino acid glucagon sequence plus an 8-amino acid C-terminal extension encoded by intervening peptide-1 (IP-1): KRNRNNIA at positions 30-37.

---

Molecular Structure and Receptor Pharmacology

Primary Structure

Oxyntomodulin's sequence is:

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala

Positions 1-29 are identical to pancreatic glucagon. The C-terminal octapeptide (KRNRNNIA) distinguishes OXM from glucagon and critically modifies its receptor selectivity profile.

GLP-1 Receptor Binding

OXM activates GLP-1R with approximately 10-100-fold reduced potency compared to native GLP-1(7-36)NH₂, depending on the signaling pathway assessed. Despite this lower affinity, OXM achieves physiologically meaningful GLP-1R engagement at the elevated postprandial concentrations secreted by intestinal L-cells. Mechanistic studies indicate OXM adopts an α-helical conformation in the mid-region (residues 10-25) critical for receptor engagement, and that the C-terminal extension alters the binding geometry at GLP-1R compared to native GLP-1 — explaining its partial agonist behavior in some downstream pathways (Pocai 2009; PMC2750209).

Notably, OXM behaves as a partial agonist for GLP-1R-mediated β-arrestin recruitment while acting as a full agonist for cAMP accumulation, a biased signaling pattern that has drawn significant mechanistic interest (Jorgensen et al., 2007; PMID: 17395766). This signaling bias may contribute to the distinct physiological profile OXM produces relative to pure GLP-1R agonists.

Glucagon Receptor Binding

At GCGR, OXM binds with approximately 30-100-fold lower potency than glucagon itself, owing in part to steric interactions between Arg18 (in the mid-helix) and extracellular loop 1 (ECL1) of GCGR. Structural studies using cryo-EM have helped visualize how OXM simultaneously occupies binding contacts at both GLP-1R and GCGR — work elegantly summarized in the 2023 PNAS structural analysis of dual agonism (Zhang et al. 2023; PNAS doi:10.1073/pnas.2303696120). This structural understanding has directly informed medicinal chemistry campaigns to engineer optimized dual agonists with enhanced GCGR potency and extended half-life.

The IP-1 octapeptide C-terminal extension of OXM is not merely a structural curiosity. Truncation experiments demonstrate that removal of IP-1 reverts OXM to glucagon-like GCGR-dominant pharmacology and dramatically reduces its appetite-suppressing properties — suggesting IP-1 is mechanistically integral to OXM's biological uniqueness.

---

Physiological Effects

The defining feature of oxyntomodulin's biology is the production of effects exceeding those achievable by either GLP-1 or glucagon alone. This synergism — not simple additive action — is what makes the OXM pharmacophore so valuable for metabolic research.

Appetite Suppression and Food Intake Reduction

Rodent studies have shown that central administration of OXM into the arcuate nucleus suppresses food intake through NPY/AgRP neuron inhibition, paralleling the central actions of GLP-1 while also engaging hypothalamic circuits sensitive to GCGR signaling. In comparative studies, OXM and GLP-1 differed in their dose-response relationships for food intake suppression and energy expenditure — OXM showing additional thermogenic actions not produced by GLP-1 alone (Dakin et al. 2004; PMID: 15300587).

Enhanced Energy Expenditure

Perhaps the most physiologically distinctive feature of OXM is its capacity to increase resting energy expenditure (REE) — an effect attributable to GCGR activation that GLP-1R agonism alone does not reliably produce. Glucagon is a well-established thermogenic agent through its actions on brown adipose tissue (BAT) uncoupling protein-1 (UCP1) expression and hepatic lipid oxidation. OXM captures this thermogenic signal via its GCGR component.

A key randomized controlled trial demonstrated that four-day subcutaneous OXM self-administration (three times daily preprandially) significantly increased 24-hour energy expenditure by approximately 6% above baseline in overweight and obese research subjects, compared to saline control — while simultaneously reducing energy intake by ~250 kcal/day at the end of the trial period (Wynne et al. 2006; PMID: 16619056). This dual negative energy balance mechanism — less intake, more expenditure — is considered a key advantage of OXM-based pharmacology over pure GLP-1R agonism.

Glycemic Regulation and Insulin Secretion

OXM's glycemic effects are complex and partially GLP-1R-dependent. Through GLP-1R, OXM potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells in a glucose-dependent manner — the same mechanism underlying GLP-1's favorable glycemic safety profile (low hypoglycemia risk at physiological glucose levels).

A critical 2018 clinical study evaluated native OXM infusion in obese humans with and without type 2 diabetes, demonstrating significant glucoregulatory effects that were partially independent of the associated changes in body weight or food intake (Tan et al. 2018; PMID: 29545266). This finding established that OXM's glycemic actions are not simply secondary to caloric restriction or weight loss — they involve direct beta cell potentiation and possibly hepatic insulin sensitization via GCGR signaling.

The simultaneous engagement of GCGR also creates a theoretically counteracting glucagonotropic signal (elevated hepatic glucose output). Preclinical evidence suggests that at the lower GCGR occupancy produced by OXM's reduced GCGR potency, the thermogenic and lipolytic GCGR effects predominate over frank hyperglycemia — a pharmacological balance that makes OXM-class molecules suitable for metabolic research despite the historical concern about glucagon-mediated glycemia.

Gastric Emptying

OXM delays gastric emptying, primarily via GLP-1R activation in the enteric nervous system and vagal efferents. Delayed gastric emptying contributes to prolonged satiety signaling and blunted postprandial glucose excursions — a shared mechanism with GLP-1 and GIP that provides another angle for metabolic research investigation. In a head-to-head infusion study comparing OXM, glucagon, and GLP-1 on multiple endpoints, OXM produced the most pronounced delay in gastric emptying among the conditions tested (Tan et al. 2015; PMID: 26445112).

Hepatic and Lipid Metabolism

Through GCGR engagement, OXM activates hepatic gluconeogenesis and fatty acid oxidation. In the context of obesity research, the hepatic GCGR component of OXM pharmacology is of particular interest for MASH (metabolic dysfunction-associated steatohepatitis) research, as glucagon receptor activation reduces hepatic lipid accumulation through enhanced β-oxidation and reduced de novo lipogenesis. Preclinical OXM analog research has demonstrated clear reductions in hepatic steatosis scores alongside obesity reversal in rodent models.

---

Secretion, Circulating Levels, and Pharmacokinetics

Postprandial Secretion from L-Cells

Oxyntomodulin is co-secreted from intestinal L-cells alongside GLP-1, GLP-2, and PYY in response to luminal nutrient stimulation. L-cells are enteroendocrine cells most abundant in the distal small intestine (ileum) and colon, though they are present throughout the intestinal mucosa. Fat and protein are particularly potent secretagogues; short-chain fatty acids (SCFAs) from microbial fermentation in the colon stimulate distal L-cells via GPR41 and GPR43 signaling.

Plasma OXM rises 2-4 fold above fasting levels within 30-60 minutes of meal ingestion, roughly paralleling the GLP-1 secretion profile. In research settings, OXM is measured via specific immunoassays, though accurate quantification requires careful sample handling: OXM is susceptible to DPP-4 cleavage, and plasma must be collected in DPP-4 inhibitor-containing tubes or processed immediately on ice to obtain accurate intact OXM measurements.

Short Half-Life and DPP-4 Vulnerability

Circulating OXM is rapidly degraded, with an estimated plasma half-life of approximately 12 minutes in humans, primarily via DPP-4-mediated cleavage of the N-terminal His-Ser dipeptide (identical mechanism to GLP-1 degradation). The truncated product OXM(3-37) retains some receptor activity at GCGR but shows markedly reduced GLP-1R potency.

Additional degradation pathways involve neutral endopeptidase 24.11 (NEP, neprilysin), which cleaves OXM at multiple internal sites. The short half-life of native OXM was a fundamental driver of early medicinal chemistry efforts to develop DPP-4-resistant analogs. Strategies employed included N-terminal amino acid substitution (Aib at position 2), mid-helix stapling, fatty acid conjugation (analogous to semaglutide's albumin binding strategy), and C-terminal modifications — work reviewed comprehensively in the development of DPP-IV-resistant OXM derivatives (Santoprete et al. 2011; PMID: 21294225).

Elevated Levels After Bariatric Surgery

One of the most physiologically important discoveries in OXM research came from bariatric surgery studies. Following Roux-en-Y gastric bypass (RYGB), circulating OXM levels increase dramatically — in some studies more than 10-fold above pre-operative fasting levels — during postprandial periods. This OXM surge, co-occurring with elevated GLP-1 and PYY, is believed to contribute substantially to the appetite suppression, improved glycemia, and weight maintenance observed after RYGB. OXM and glicentin may also serve as predictive biomarkers for the degree of weight loss and dietary preference change following bariatric interventions (Holst et al. 2020; PMID: 32016415).

---

Clinical Research Evidence

Human Appetite and Body Weight Studies

The clinical research record for native oxyntomodulin spans three primary endpoints: food intake reduction, body weight, and energy expenditure.

Energy expenditure: The companion RCT (Wynne et al. 2006) quantified a significant ~6% increase in 24-hour energy expenditure in OXM-treated subjects, a finding not observed with GLP-1 infusion alone in comparative studies — reinforcing the unique GCGR contribution to OXM's metabolic phenotype (PMID: 16619056).

Glycemia independent of weight: Tan et al. (2018) showed that OXM produced glucose-lowering and insulinotropic effects measurable independently of the weight loss and caloric restriction it also produced, establishing direct pancreatic and hepatic actions (PMID: 29545266).

Comparative Studies: OXM vs. GLP-1 vs. Glucagon

A 2015 study by Tan et al. directly compared IV infusion of oxyntomodulin, GLP-1, glucagon, and a GLP-1 + glucagon combination in a crossover design in healthy volunteers. All active conditions reduced food intake, but OXM produced the most sustained reduction in appetite scores. Resting energy expenditure was significantly elevated only in OXM and glucagon conditions — reinforcing that the GCGR component is required for this metabolic action (PMID: 26445112). This study provided critical mechanistic clarity: OXM's metabolic superiority over GLP-1 monotherapy is attributable to, and requires, its GCGR engagement.

OXM as a Metabolic Biomarker

More recent research has explored native OXM circulating levels as a metabolic biomarker. A 2025 study found that obese individuals display paradoxically elevated fasting and postprandial OXM levels compared to lean controls, suggesting a compensatory but insufficiently effective upregulation of the OXM axis in metabolic disease — a pattern paralleling leptin resistance. OXM levels correlated positively with fasting insulin, C-peptide, and visceral adiposity, positioning OXM as a potential index of adipose dysfunction and incretin dysregulation beyond simple measurement of GLP-1 or insulin alone.

---

OXM as the Template for the Dual GLP-1/Glucagon Agonist Drug Class

The translational significance of oxyntomodulin research extends far beyond the native peptide itself. The OXM pharmacophore — a single peptide capable of co-activating GLP-1R and GCGR — served as the direct molecular template for an entire class of engineered therapeutics now advancing through clinical development.

From Native OXM to Optimized Analogs

Native OXM's liabilities as a therapeutic are well-characterized: rapid DPP-4 degradation (t₁/₂ ~12 min), relatively low receptor potency (10-100-fold below cognate ligands), and no fatty acid modification for albumin binding. Early analog engineering efforts introduced Aib (α-aminoisobutyric acid) at position 2 to confer DPP-4 resistance, C-terminal lipidation for albumin binding, and mid-helix stabilization via α-helical enhancers — collectively extending half-life from minutes to days.

The OXM-derived analog trajectory has produced multiple clinical-stage compounds:

• •Mazdutide (IBI362/LY3305677): A GLP-1/glucagon dual agonist directly derived from mammalian OXM, with extensive preclinical and phase II data showing substantial weight reduction and hepatic steatosis improvement. (See full mazdutide research profile.)
• •Survodutide (BI 456906): Another OXM-derived backbone compound with strong preclinical obesity reversal data. (See survodutide research profile.)
• •MEDI0382 (cotadutide): An early-stage OXM analog demonstrating body weight reduction and hepatic benefits in clinical trials.

The design logic in each case begins with OXM's core sequence and then applies medicinal chemistry to achieve: (1) DPP-4 resistance, (2) prolonged half-life through albumin binding or PEGylation, (3) balanced GLP-1R/GCGR potency tuned to the desired therapeutic profile, and (4) injectable depot formulation capability (Cegla et al. 2023; PMID: 36669563).

Why Dual Agonism Matters for Research

The pharmacological rationale for dual GLP-1R/GCGR agonism over pure GLP-1R agonism rests on three complementary mechanisms:

1. Greater weight loss: GCGR activation adds thermogenic energy expenditure atop the caloric restriction mediated by GLP-1R, producing a more negative energy balance.

2. MASH/steatosis benefit: Glucagon receptor activation in the liver enhances fatty acid oxidation and reduces de novo lipogenesis — effects not obtained from GLP-1R activation alone.

3. Cardiovascular outcomes: Emerging data suggest GCGR activation in the heart and vasculature may produce complementary cardioprotective effects, though this remains an active area of investigation.

A comprehensive 2025 review on dual GLP-1R/GCGR agonism evaluated clinical evidence across the cardiometabolic continuum, noting that compounds in this class consistently outperform GLP-1R monotherapy for weight loss while maintaining comparable or superior glycemic control (PMC12326405).

---

Comparison to GLP-1 and Glucagon

This comparative framework highlights why OXM occupies a distinct pharmacological niche: it combines the appetite-suppressive signaling of GLP-1R with the thermogenic and hepatic signaling of GCGR, without the full hyperglycemic liability of a pure glucagon agonist. The "diluted" GCGR potency of native OXM (versus full glucagon) appears to be physiologically intentional — preserving beneficial glucagon actions while avoiding frank hyperglycemia.

---

Research Applications

In Vitro Applications

Oxyntomodulin is used in cell culture research to:

• •Characterize GLP-1R/GCGR dual-agonist signaling pathways (cAMP, β-arrestin recruitment, ERK phosphorylation)
• •Develop and validate competitive binding assays for GLP-1R and GCGR
• •Evaluate biased agonism at GLP-1R (cAMP vs. β-arrestin 2)
• •Study mitochondrial metabolism and lipid oxidation in hepatocyte and adipocyte model systems
• •Serve as a reference standard for assessing OXM analog potency at native receptors

In Vivo Rodent Model Applications

In preclinical rodent research, oxyntomodulin is administered to:

• •Model the endogenous incretin response and its regulation
• •Distinguish GLP-1R vs. GCGR contributions to observed metabolic outcomes using receptor-selective knockouts or antagonists
• •Evaluate the incretin response in high-fat diet-induced obesity models
• •Serve as the parent compound comparator when evaluating engineered OXM analogs for potency and duration optimization

Structural Biology and Drug Design

Recombinant or synthetic OXM serves as a structural reference in cryo-EM and X-ray crystallography studies of GLP-1R and GCGR, providing the endogenous dual-agonist binding geometry against which therapeutic analogs are benchmarked. This structural biology function has been particularly productive since 2020, with multiple OXM-related receptor complex structures deposited in the Protein Data Bank.

---

Stability and Storage in Research Settings

Native oxyntomodulin for research use is typically supplied as lyophilized powder. Storage recommendations follow standard peptide protocols: lyophilized at −20°C in desiccated conditions, reconstituted in sterile aqueous vehicle (typically 0.9% saline with 0.1% BSA for in vivo use, or culture-grade PBS for cell work), and used within 24 hours of reconstitution for maximum bioactivity. As with GLP-1, DPP-4 inhibitors (e.g., Diprotin A or sitagliptin at 10-100 µM final concentration) are frequently added to research buffers and plasma collection tubes to preserve intact OXM during sample handling.

For accurate bioassay work, researchers should use OXM-specific immunoassays that distinguish intact OXM from the DPP-4 truncation product OXM(3-37) and from cross-reactive glicentin. Several validated ELISA platforms are commercially available specifically for intact OXM quantification in plasma samples collected in appropriate protease inhibitor cocktails.

---

Research Gaps and Future Directions

Despite a substantial research record, key questions about oxyntomodulin remain open:

1. The "obesity paradox": Why do obese individuals exhibit elevated OXM levels yet remain unresponsive to its appetite-suppressive effects? Receptor desensitization, impaired BBB transport of OXM to hypothalamic centers, or downstream signaling disruption in AgRP/NPY neurons are candidate mechanisms under investigation.

2. Central vs. peripheral actions: The relative contribution of OXM acting directly on CNS receptors (hypothalamus, NTS) versus peripheral GLP-1R/GCGR (gut-vagal afferents, pancreas, liver) to its appetite and energy effects is not fully resolved.

3. OXM and the microbiome: L-cell secretion of OXM is regulated in part by microbial fermentation products. The extent to which the gut microbiome modulates chronic OXM secretion — and whether microbiome-targeted interventions could enhance physiological OXM tone — represents an emerging research frontier.

4. Cardiovascular outcomes: Unlike GLP-1R agonists, where dedicated cardiovascular outcomes trials (LEADER, SUSTAIN-6, SOUL) have provided definitive data, the cardiovascular effects of GCGR co-activation in the OXM pharmacological class remain less characterized. This is an active area for the next generation of dual-agonist clinical trials.

5. Combination with GLP-2 and PYY: Oxyntomodulin is co-secreted with GLP-2 and PYY from the same L-cell. The physiological consequences of this co-secretion — and whether synergistic interactions among these peptides shape the postprandial satiety signal — remains incompletely understood in humans.

---

Summary

Oxyntomodulin is a 37-amino acid proglucagon-derived peptide secreted by intestinal L-cells that acts as an endogenous unimolecular dual agonist at GLP-1R and GCGR. It suppresses appetite via GLP-1R, boosts energy expenditure via GCGR, delays gastric emptying, and improves glycemia through complementary mechanisms at both receptors. Despite a short circulating half-life of ~12 minutes, native OXM has demonstrated significant weight reduction and energy expenditure increases in randomized clinical research.

Its enduring scientific importance lies in its role as the molecular template for the dual GLP-1/glucagon agonist drug class — including mazdutide, survodutide, and MEDI0382 — which are achieving superior weight loss compared to GLP-1R monotherapy in ongoing clinical investigations. For researchers studying metabolic regulation, incretin biology, or next-generation anti-obesity pharmacology, oxyntomodulin represents an indispensable model system and research tool.

---

Key References

3. Wynne K et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans. Int J Obes. 2006. PMID: 16619056

4. Dakin CL et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Endocrinology. 2004. PMID: 15300587

5. Tan TM et al. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. J Clin Endocrinol Metab. 2015. PMID: 26445112

6. Tan TM et al. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss. Diabetes. 2018. PMID: 29545266

7. Pocai A et al. Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice. Diabetes. 2009. PMC2750209

8. Cegla J et al. Emerging roles of oxyntomodulin-based GLP-1/glucagon co-agonist analogs in diabetes and obesity. Curr Opin Pharmacol. 2023. PMID: 36669563

9. Holst JJ et al. Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. J Clin Endocrinol Metab. 2020. PMID: 32016415

10. Santoprete A et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci. 2011. PMID: 21294225

11. Zhang X et al. Structural analysis of the dual agonism at GLP-1R and GCGR. PNAS. 2023. doi:10.1073/pnas.2303696120

12. Kueh MT et al. Oxyntomodulin physiology and its therapeutic development in obesity and associated complications. J Physiol. 2025. PMID: 39495024